(Boursier.com) — Pfizer fell slightly in pre-session on Wall Street after maintaining its sales forecast for its oral treatment for Covid-19, Paxlovid. The pharmaceutical giant thus still expects its revenue from the sale of its pill to reach 22 billion dollars this year, against a consensus positioned at 26.1 billion dollars. “Overall, we expect that recent trends to expand access (to Paxlovid), as well as inquiries received from governments as the virus mutates and causes spikes in infections around the world, lead to an increase in orders in the coming months,” said Pfizer boss Albert Bourla. The company also reiterated its forecast of revenue from the vaccine developed with BioNTech at $32 billion. Overall, the New York-based group is banking on 2022 revenues of between $98 billion and $102 billion.
In the first quarter, the firm achieved an adjusted EPS of $1.62 against $0.95 a year earlier, for revenues of $25.7 billion, up 77% ($24.36 billion consensus) . At the request of the Securities and Exchange Commission, several pharmaceutical companies have adjusted their forecasts to include spending related to milestone payments and acquisitions. Pfizer has accordingly lowered its annual adjusted earnings per share target to $6.25-6.45 from a previous guidance of $6.35-6.55, primarily due to the impact of these expenses. .
©2022 Boursier.com